Champions Oncology, Inc. - CSBR STOCK NEWS

Champions Oncology (CSBR) reported record revenue of $11.3 million for Q1 FY2022, marking an 18% increase year-over-year. The company achieved a non-GAAP income of $422,000, while operational losses were $175,000, impacted by increased R&D expenses. Total costs rose 20% to $11.4 million. Gross margins improved to 52% due to internalizing lab work. The firm continues to expand its Software as a Service (SaaS) offerings and therapeutic target discovery initiatives, ending the quarter with a solid cash position of $4 million.

Champions Oncology, Inc. (CSBR) is set to announce its financial results for the first quarter ending July 31, 2021, on September 13, 2021, after market close. A conference call will be held at 4:30 P.M. EDT to discuss these results. Interested parties can join via phone or access a replay within 72 hours on the company's website. Champions Oncology is recognized for its transformative technology solutions in oncology drug discovery and development, utilizing advanced research and experimental tools.

Champions Oncology (NASDAQ: CSBR) has expanded its corporate strategy to enter the drug discovery and development space, enhancing its oncology technology solutions. The company operates three business units: the Research Services Business, the Research Software Business featuring Lumin Bioinformatics, and the newly launched Discovery and Innovation Business. This strategic move is based on a unique dataset derived from a 'living tumor bank', allowing for improved drug response insights and therapeutic target discovery using advanced computational methods.

Champions Oncology (NASDAQ:CSBR) reported record annual revenue of $41 million for the fiscal year ending April 30, 2021, marking a 28% year-over-year growth. The fourth quarter alone saw revenue rise by 21% to $10.6 million. Significant investments in research, development, and new service capabilities contributed to an operating income of $2.1 million, reversing prior losses. The company's gross margin improved to 48%. Despite a net cash use of $1.7 million for the year, the company ended with $4.7 million in cash and no debt.

Champions Oncology (NASDAQ:CSBR) will release its fourth quarter financial results on July 22, 2021, before market open. The company specializes in oncology technology solutions aimed at enhancing drug discovery through advanced pharmacology, biomarker, and data platforms. A conference call will follow on the same day at 8:30 a.m. EDT to discuss the financial results. Stakeholders can join by calling 877-407-8035. A recording of the call will be available post-event.

Champions Oncology (NASDAQ:CSBR) has announced a strategic partnership with BGI Americas, enhancing their Lumin Bioinformatics platform. This collaboration grants BGI access to Champions' extensive cancer datasets, facilitating advanced analysis of proteomics data for their clients. BGI will utilize its Mass Spectrometry Center to assist in biomarker discovery and validation solutions, allowing both companies to offer a streamlined workflow from data generation to interpretation. This partnership positions Champions as a leader in data-driven oncology solutions.

Champions Oncology (NASDAQ:CSBR) reported impressive third-quarter financial results for fiscal 2021, achieving a record revenue of $10.8 million, a 20% year-over-year increase. The company reported a non-GAAP income from operations of $1.3 million, up from $881,000 in the same quarter last year. Despite a rise in total operating expenses by 17.1% to $10 million, Champions continues to invest in product development and expansion. Their cash balance improved significantly to $7.4 million compared to $3.3 million a year ago, with no debt reported.

Champions Oncology, Inc. (NASDAQ:CSBR) will announce its third-quarter financial results for the period ending January 31, 2021, on March 11, 2021, after the market closes. A conference call to discuss the results will take place at 4:30 p.m. EST on the same day. Interested parties can join by calling 877-407-8035 (Domestic) or 201-689-8035 (International). A replay will be available shortly after the call. Champions Oncology focuses on transforming drug discovery through innovative pharmacology and data platforms.

Champions Oncology (NASDAQ:CSBR) announced the appointment of Rob Brainin to its Board of Directors, enhancing its expertise in drug discovery through innovative data platforms. With over 15 years in life sciences, Brainin is expected to accelerate the company's data platform development. His previous leadership roles include CEO of Genuity Science and VP at Illumina. The company also noted the resignation of board member Abba Poliakoff, thanking him for his contributions.